EDIT - Editas Medicine - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

EDIT is currently covered by 12 analysts with an average price target of $3.74. This is a potential upside of $1.05 (39.03%) from yesterday's end of day stock price of $2.69.

Editas Medicine's activity chart (see below) currently has 158 price targets and 127 ratings on display. The stock rating distribution of EDIT is 33.33% HOLD, 61.9% BUY and 4.76% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50.21% with an average time for these price targets to be met of 145.42 days.

Highest price target for EDIT is $6, Lowest price target is $1, average price target is $3.63.

Most recent stock forecast was given by YANAN ZHU from WELLS FARGO on 03-Sep-2025. First documented stock forecast 29-Feb-2016.

Currently out of the existing stock ratings of EDIT, 7 are a HOLD (33.33%), 13 are a BUY (61.9%), 1 are a SELL (4.76%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$4

$0.92 (29.87%)

$3

2 months 3 days ago
(03-Sep-2025)

4/9 (44.44%)

$1.5 (60.00%)

51

Buy

$6

$2.92 (94.81%)

$4

2 months 24 days ago
(13-Aug-2025)

2/7 (28.57%)

$2.92 (94.81%)

87

Buy

$4

$0.92 (29.87%)

$5

5 months 24 days ago
(13-May-2025)

3/6 (50%)

$2.5 (166.67%)

54

Sell

$9

10 months 21 days ago
(16-Dec-2024)

2/2 (100%)

$0.14 (1.58%)

9

$3

$-0.08 (-2.60%)

$5

10 months 24 days ago
(13-Dec-2024)

8/12 (66.67%)

$1.56 (108.33%)

200

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is EDIT (Editas Medicine) average time for price targets to be met?

On average it took 145.42 days on average for the stock forecasts to be realized with a an average price target met ratio 50.21

Which analyst has the current highest performing score on EDIT (Editas Medicine) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on EDIT (Editas Medicine)?

Steven Seedhouse works at CANTOR FITZGERALD and has 4 price targets and 3 ratings on EDIT

Which analyst is the currently most bullish on EDIT (Editas Medicine)?

Cory Kasimov with highest potential upside - $26.92

Which analyst is the currently most reserved on EDIT (Editas Medicine)?

Greg Harrison with lowest potential downside - -$2.08

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?